Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp - Seite 2
This new device will also be the basis of a workshop, where BioCamp participants will work in groups to develop strategies to successfully include this new technology in a clinical setting. On the final day of the program, the groups will present their strategy proposals to a jury of experts. The jury will select three individual winners and one winning team based on their contribution, performance, leadership and teamwork. The workshop will give students first-hand experience of working in a diverse cross-cultural project team.
About BioCamp
The Novartis International Biotechnology Leadership Camp is a 3-day biotechnology seminar for top graduate and postgraduate students interested in pursuing a career in biotechnology.
BioCamp participants get an insider's perspective on the challenges and opportunities in biotechnology today through seminars led by Novartis leaders and experts from around the world. Workshops are designed to give participants the tools they need to become successful biotech managers and entrepreneurs.
Launched in 2003 in Taiwan, BioCamp has developed into an international forum for science and business students from around the world to learn, exchange ideas and work together in a highly competitive business environment. Today's seminar marks the seventh international BioCamp hosted at the state-of-the-art Novartis global headquarters in Basel, Switzerland.
Lesen Sie auch
Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "opportunities," "potential," "will," "can," "aims," "under development," "may," "designed," or
similar terms, or by express or implied discussions regarding potential approvals for the movement recording system under development, or regarding potential future revenues from such system. You
should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to
significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary
materially from those set forth in the forward-looking statements. There can be no guarantee that the movement recording system under development will be submitted or approved for sale in any
market, or at any particular time. Nor can there be any guarantee that such system will be commercially successful in the future. In particular, management's expectations regarding such system
could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry
conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety, quality or manufacturing issues, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.